A neurysmAl SAH remains a stroke subtype with high morbidity and mortality rates despite considerable advances in its diagnosis and management during the last decade. 27 A major reason for an unfavorable outcome following SAH is DIND caused by arterial cerebral vasospasm typically developing between 4 and 10 days after ictus. 4, 12, 21 Poor outcome (death or dependence) has been reported in 70% of the patients who have suffered an SAH, and it has been estimated that a DIND is implicated in ~ one-third of these cases. 3, 13 The pathophysiological mechanism underlying SAHrelated vasospasm is largely unknown, and medical treatment has so far failed to prevent its occurrence. Treatment options include hypervolemia, hemodilution, and induced hypertension (so-called triple-H therapy); calcium antagonists; and angioplasty. 16 Based on the hypothesis that vasospasm is at least partially dependent on calcium influx in vascular smooth-muscle cells, the dihydropyridine calcium antagonist nimodipine was introduced during the 1980s as a prophylactic treatment in patients who experienced an SAH. Randomized trials have demonstrated that treatment with nimodipine reduces the proportion of patients with DIND and poor outcome as well as the number of cerebral infarctions 3, 19 and that this treatment is cost-effective. 11 It is now common practice in most centers to administer nimodipine to all patients who have had an SAH. Because most trials have been conducted with peroral administration of the drug, this route has become the most common. However, despite the fact that the intravenous administration of nimodipine can induce arterial hypotension, is substantially more expensive, and has not proven beneficial in randomized trials, several centers routinely administer Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration Object. The calcium antagonist nimodipine has been shown to reduce the incidence of ischemic complications following aneurysmal subarachnoid hemorrhage (SAH). Although most randomized studies have been focused on the effect of the peroral administration of nimodipine, intravenous infusion is an alternative and the preferred mode of treatment in many centers. It is unknown whether the route of administration is of any importance for the clinical efficacy of the drug.
Methods. One hundred six patients with acute aneurysmal SAH were randomized to receive either peroral or intravenous nimodipine treatment. The patients were monitored for at least 10 days after bleeding in terms of delayed ischemic neurological deficits (DINDs) and with daily measurements of blood flow velocities in the middle cerebral arteries by using transcranial Doppler ultrasonography. Three months after SAH, clinical outcome and new cerebral infarctions according to MR imaging studies were recorded.
Results. Baseline characteristics (age, sex distribution, clinical status on admission, radiological findings, and aneurysm treatment) did not differ between the treatment groups. There was no significant difference in the incidence of DINDs (28 vs 30% in the peroral and intravenous groups, respectively) or middle cerebral artery blood flow velocities (> 120 cm/second, 50 vs 45%, respectively). Clinical outcome according to the Glasgow Outcome Scale was the same in both groups, and there was no difference in the number of patients with new infarctions on MR imaging.
Conclusions. The results suggest that there is no clinically relevant difference in efficacy between peroral and intravenous administration of nimodipine in preventing DINDs or cerebral vasospasm following SAH. nimodipine intravenously. A major argument for a parenteral route has been the demonstration of more reliable and stable plasma concentrations of nimodipine. 14, 24, 28 A direct comparison between nimodipine administered perorally and intravenously in regard to clinically meaningful differences has never been published.
In the present study, patients who had an SAH were prospectively randomized to receive either peroral or intravenous treatment with nimodipine. We evaluated the incidence of clinical signs of vasospasm in the acute phase as well as the clinical and radiological outcome 3 months after SAH.
Methods
The study was undertaken in the Department of Neurosurgery, Lund University Hospital, which is the only neurosurgical department in the southernmost part of Sweden, covering a population of 1.6 million. Patients were recruited during a 30-month period between October 2002 and March 2005. Eligible for inclusion were patients with aneurysmal SAH in whom randomization and nimodipine treatment could be initiated within 48 hours after ictus. The study was approved by the ethics committee at the Lund University Medical Faculty and Medical Products Agency in Sweden. Written informed consent was obtained from either the patient or his or her next of kin.
The diagnosis of SAH was made using CT or lumbar puncture if the CT failed to detect any blood. Clinical status on admission was assessed using the Hunt and Hess scale. 9 Blood distribution on CT was graded according to the Fisher scale. 5 The presence of an intracranial aneurysm was confirmed with DS angiography within 24 hours after admission. Only patients with an angiographically verified aneurysm qualified for the study.
All patients were admitted to an ICU dedicated to neurosurgical patients where the initial treatment and monitoring was performed. Aneurysms were occluded using either an exovascular (clipping) or endovascular technique (coiling), usually within 48 hours of SAH. Tranexamic acid was administered to prevent early rebleeding 8 prior to permanent occlusion (1 g intravenously, every 6 hours).
Randomization and Treatment Protocol
Patients were randomized to receive either peroral or intravenous nimodipine by drawing a sealed envelope. One hundred slips with the text "per os" and 100 with "iv infusion" were produced. All slips were put in identical envelopes, which were sealed and then shuffled. After inclusion into the study, an envelope was drawn for each consecutive patient. Nimodipine was administered as 2 30-mg tablets by mouth every 4 hours or as a continuous intravenous infusion of 0.2 mg/ml at 10 ml/hour (Nimotop, Bayer AG). If the patient became hypotensive (systolic blood pressure < 110 mm Hg), a temporary reduction in the infusion rate was allowed (typically to 5 ml/hour). Patients who were unable to swallow were given crushed tablets with water via a nasogastric tube. Nimodipine treatment was continued for at least 10 days. Treatment exceeded 10 days if the patient showed signs of a DIND or increased flow velocities as indicated by TCD ultrasonography (see below). Crossover between treatment modalities was not allowed. The route of administration could not be blinded to the clinician. If a patient assigned to peroral treatment experienced significant gastric retention suggesting disturbed absorption of nimodipine, he or she was withdrawn from the study.
Clinical Monitoring
Neurological status was monitored and documented 3-12 times every 24 hours, depending on clinical status. Clinical deterioration with the onset of new focal neurological deficits or a diminished state of consciousness (decline of > 1 point on the Glasgow Coma Scale) lasting for at least 24 hours was interpreted as a DIND if other causes such as hydrocephalus, rebleeding, or hyponatremia could be excluded. Sedated patients on ventilator treatment were assessed neurologically through the temporary discontinuation of sedation. Measurements of blood flow velocities in both MCAs according to TCD ultrasonography were obtained on a daily basis. Blood flow velocities > 120 cm/second or increases of > 50 cm/second in 24 hours in the MCA were interpreted as indicative of vasospasm.
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Patients with a DIND or increased blood flow velocities received, in addition to the nimodipine, hypervolemia-hemodilution therapy. Induced hypertension was used very rarely and thus was not recorded in the study. An external ventricular drain was inserted in comatose patients and in those with clinical deterioration due to hydrocephalus.
At 3 months after SAH, patients were assessed according to the GOS. 10 At the same time, MR imaging was performed to detect new areas of cerebral infarction. Highsignal lesions on T2-weighted or FLAIR MR sequences were compared with hypodense areas on the original CT scans. A neuroradiologist blinded to the treatment groups performed the radiological evaluation.
Study End Points
The primary objective of this study was to determine whether the mode of nimodipine administration (peroral or intravenous) influences the incidence of DINDs. Secondary end points were blood flow velocities in the MCAs as measured by TCD ultrasonography, clinical outcome based on the GOS, and new infarctions according to MR imaging studies 3 months after SAH. We also analyzed the need for hypervolemia-hemodilution therapy as well as the time required in the ICU.
Statistical Analysis
Group comparisons were performed using the chisquare test for proportions and the Student t-test for the number of days with elevated TCD ultrasonography values and the number of days in the ICU. Probability values < 0.05 (2-tailed) were considered statistically significant.
Results
Of 171 patients admitted to our center with a diagnosis of SAH, 106 were randomized in the study. Forty-nine patients were randomized to the peroral group and 57 to the intravenous group. The main reasons for not participating in the study were an inability to give informed consent (early death and/or no relatives available), an angiogram negative for aneurysm, and a late arrival to our unit (> 48 hours after ictus). During the study process repeated interim analyses were performed, and based on the results the inclusion process was interrupted after 106 patients. One patient in the intravenous group was lost at follow-up. Three patients in the peroral group were excluded due to vomiting or gastrointestinal paralysis suggesting impaired drug absorption. Clinical condition on admission did not differ between the treatment groups, and neither did the amount of bleeding on CT (Fisher grade) nor age distribution (Table 1) . Sex distribution, type of aneurysm treatment (open surgery or endovascular therapy), and number of patients with external ventricular drainage were also similar in both groups. In contrast, aneurysm location differed between the 2 groups; there were more internal carotid artery (ophthalmic, posterior communicating, anterior choroidal, and internal carotid artery bifurcation) aneurysms as the cause of SAH in the peroral group (chi-square = 8.50, p < 0.01) and more anterior cerebral artery (including anterior communicating and pericallosal artery) aneurysms in the intravenous group (chi-square = 5.23, p = 0.02). The proportion of patients with bacterial ventriculitis did not differ significantly between the groups.
There was no difference in the occurrence of DINDs between treatment groups: 13 (28%) of 46 patients in the peroral and 17 (30%) of 57 in the intravenous group (chisquare = 0.03, p = 0.86; Table 2 ).
Measurements of blood flow velocity in the MCA according to TCD ultrasonography were also similar in both groups (Table 2 ). In 4 patients (2 in each group), reliable TCD ultrasonography examinations were not possible because of the cranial thickness. Twenty-two (50%) of 44 patients in the peroral group and 25 (45%) of 55 in the intravenous group had blood flow velocities > 120 cm/ second (chi-square = 0.20, p = 0.65). The average number of days with blood flow velocities > 120 cm/second were also similar: 2.3 ± 3.1 (mean ± SD) in the peroral group and 2.1 ± 3.2 in the intravenous group (t = 0.19, p = 0.85). Increases of > 50 cm/second in 24 hours were seen in 7 (16%) of 44 patients and 7 (13%) of 55 in the peroral and intravenous groups, respectively (chi-square = 0.20, p = 0.65). Histograms of the daily blood flow velocities in both MCAs were strikingly similar (Fig. 1) . The number of patients treated with hemodilution and hypervolemia, an indirect sign of vasospasm or impending vasospasm as judged by the clinician, was similar in both groups (52 and 53%, chi-square = 0.00, p = 0.96). The mean time required in the ICU did not differ between the groups: 10.9 ± 7.5 and 10.9 ± 7.1 days in the peroral and intravenous groups, respectively (t = 0.02, p = 1.00).
The distribution of clinical outcomes 3 months after SAH was similar in both groups (Table 3) . None of the patients ended up in a vegetative state (GOS Score 2). Five patients in the peroral group and 8 in the intravenous group died. The number of patients with a favorable clinical outcome (GOS Score 4 or 5) did not differ between therapeutic modalities: 35 (76%) of 46 in the peroral group and 39 (70%) of 56 in the intravenous group (chi-square = 0.53, p = 0.47). The number of patients with chronic hydrocephalus requiring cerebrospinal fluid shunting was also analyzed. In the peroral group, 12 (26%) of 46 patients received a shunt, as compared with 10 (19%) of 56 in the intravenous group (chi-square = 1.01, p = 0.31).
Magnetic resonance imaging follow-up was possible in 33 patients in the peroral group and 41 in the intravenous group 3 months after SAH. Reasons not to perform MR imaging included death, claustrophobia, and pacemaker implant. The number of patients with new infarctions did not differ significantly between the groups: 14 (42%) of 33 patients in the peroral and 18 (44%) of 41 in the intravenous group (chi-square = 0.02, p = 0.90). An analysis of only those who had clinical signs of vasospasm-that is, either a DIND or pathological TCD ultrasonography measurements-did not reveal any significant differences in the number of infarctions between treatment groups (Table 4 ). In surviving patients in whom MR imaging was contraindicated, a follow-up CT was performed. No difference in new infarctions (hypodense areas) was detected, but the groups were too small for statistical analysis to be meaningful. 
Discussion
The present study was designed to investigate whether the peroral administration of nimodipine is as efficient as an intravenous route in preventing ischemic complications following aneurysmal SAH. The comparison of peroral and intravenous administrations revealed no differences in the occurrence of DINDs, flow velocities in the MCA according to TCD ultrasonography recordings, the need for hypervolemia-hemodilution therapy, or the length of stay in the ICU. In addition, there were no differences in clinical outcome or number of new infarctions on imaging at the 3-month follow-up. The strikingly similar results for the 2 treatment modalities were consistent for all studied variables, which suggest that the findings are reliable despite the relatively small number of patients. The proportion of patients that had a DIND (30%) or increased blood flow velocities in the MCA (50%) is in agreement with values in several previous studies. 3, 6, 12, 17, 25, 27 A favorable clinical outcome (GOS Score 4 or 5) in 70-75% of patients is also in keeping with data in the modern literature, 18, 22, 26 suggesting that our study population is, in general, representative of patients who have had an SAH. A control group without nimodipine was not included in our study because to do so could have been considered unethical and made patient recruitment more difficult.
The gold standard for diagnosing cerebral vasospasm is DS angiography, which can detect vasospasm in up to 70% of patients who have had an SAH. 12 Thus, given its potentially greater sensitivity, angiography might have detected differences in efficacy between peroral and intravenous administrations in the present study. Nonetheless, because DS angiography carries a low risk of vascular complications (thromboembolism or dissection) and because we do not routinely use angiography to detect vasospasm in patients who have had an SAH, this imaging method was not adopted in our study for practical and ethical reasons. Note, however, that TCD ultrasonography is a safe and noninvasive technique and has been shown to correspond well with radiological findings of cerebral vasospasm. 15, 23, 29 A potential statistical bias in the study groups might be the fact that 3 patients in the peroral group were excluded because of gastric retention and vomiting, probably causing inferior drug absorption. It is possible that these patients were in worse clinical condition and therefore might have been more prone to vasospasm. Such bias is difficult to avoid with our study design, and it would have been unethical not to offer such patients intrave- nous treatment (thus leading to exclusion from the study as crossover was not allowed). A power analysis was not conducted when designing the study given that our purpose was to determine whether peroral and intravenous nimodipine treatment had similar efficacy in preventing cerebral ischemia and not primarily to detect any actual differences. Instead, repeated interim analyses were performed to determine the size of the study. As in previous randomized studies on the clinical efficacy of nimodipine, 3, 19 neither plasma nor cerebrospinal fluid concentrations were measured. Although the pharmacokinetics of intravenous nimodipine have been thoroughly investigated, 14 relatively little is known concerning the pharmacokinetics of peroral nimodipine. 24, 28 Vinge and colleagues 28 have demonstrated considerable variations in nimodipine concentrations after peroral administration (range < 3-96 ng/ml, average 13.2 ng/ml prior to next oral dose at 45 mg every 4 hours) as compared with those after intravenous delivery when levels were more stable (range 15-58 ng/ml, average 27 ng/ml at 2 mg/hour). The large variations in plasma concentration with oral treatment probably reflect variability in first-pass elimination. 28 In a pilot study by Soppi et al., 24 plasma concentrations of nimodipine varied substantially after peroral administration (area under the curve, range 0.1-21 µg × min/ml) as compared with intravenous administration (range 2-18 µg × min/ml). In addition, the absorption of peroral nimodipine was affected in patients with a decreased level of consciousness, and concomitant phenytoin medication may reduce its bioavailability via enzyme induction (cytochrome P450) in the liver. Other studies have shown a relationship between intravenous dosing of nimodipine and blood flow velocities in the MCA as measured with TCD ultrasonography. 23, 30 These data suggest that intravenous administration is more reliable in terms of providing optimal bioavailability of nimodipine for the patient. In fact, parenteral administration of nimodipine is the preferred treatment in several centers (particularly in Europe, personal communications) for these reasons. However, results of the present study suggest that such variation in plasma nimodipine concentrations has no significant clinical relevance. Because intravenous administration is considerably more expensive (in Sweden ~ 25-fold), carries a higher risk of induced hypotension, 7, 20 and requires invasive central venous access, our results strongly suggest that nimodipine should be administered via the oral route unless disturbed absorption or metabolism is suspected.
Conclusions
In summary, previous studies have demonstrated that calcium antagonists reduce the risk of poor outcome and secondary ischemia after aneurysmal SAH. 2, 3 Although the peroral and intravenous routes should have similar beneficial effects, benefits have been proven in clinical trials only for peroral administration. 3 Results in the present study show that the efficacy of the peroral and intravenous administration of nimodipine is similar from a practical clinical point of view. Thus, the incidence of DINDs, TCD ultrasonography measurements, clinical outcomes, and number of infarctions on MR imaging were the same for both types of administration. Because peroral treatment is safer and considerably less expensive, we suggest that parenteral nimodipine treatment be restricted to patients with derangement in enteral absorption or metabolism.
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